GENITOURINARY CANCERS

Olaparib in combination with abiraterone acetate improved progression-free survival compared with the antiandrogen agent alone in patients with metastatic castration-resistant prostate cancer, according to findings from a phase II trial presented at the 2018 ASCO Annual Meeting. The results of the trial were also published the same day in Lancet Oncology.

Sumanta Kumar Pal, MD, sheds light on the latest frontline therapeutic options for patients with mRCC and other advancements on the horizon.

According to Pfizer and Astellas, the codevelopers of enzalutamide (Xtandi), the agent has been approved by the FDA for treatment of patients with nonmetastatic castration-resistant prostate cancer.

Sunitinib alone was noninferior for median overall survival compared with sunitinib plus cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma, according to findings from the phase III noninferiority CARMENA trial.

General Cancer

Brian I. Rini, MD, discusses atezolizumab and bevacizumab as an effective frontline combination in RCC, as well as PROs with the regimen. 

Joseph F. Renzulli Jr, MD, an expert in robotic surgery for treating urologic cancers, is joining Lawrence and Memorial Hospital, an affiliate of Yale New Haven Health, in New London, Connecticut. He brings a specialized insight on diagnosing and treating prostate cancer to the growing team.

Newer MRI techniques are being tested to improve the accuracy of prostate cancer diagnosis. Three presentations during the 2018 American Urological Association Annual Meeting discussed potential approaches to reduce the need for prostate biopsies for men with prostate cancer

Charles G. Drake, MD, PhD, director of Genitourinary Oncology at New York Presbyterian/Columbia University Medical Center, discusses his thoughts on whether sunitinib would be more successful as a treatment for patients with renal cell carcinoma if used in the neoadjuvant setting.